Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on May 24, 2010 11:17pm
395 Views
Post# 17127296

RE: RE: RE: Kayday

RE: RE: RE: KaydayThe previous results were based on an EPO dose of 30,000 IU (hCG 10,000 IU)
The results expected tomorrow are from 3 cohorts plus the control group (placebo).
All cohorts were administered 10,000 IU hCG. The variance was the EPO:
Cohort 1:    4,000 IU EPO
Cohort 2:  12,000 IU EPO
Cohort 3:  20,000 IU EPO
This is the dose-response and is currently unknown. In addition to the global improvement score, the dose response is an important part of this trial.
Bullboard Posts